BioMarin Licenses Experimental Fabry Disease Drug
The company secured global rights to a new enzyme replacement therapy candidate in a deal worth up to $475 million.
Updated on Oct. 29, 2026 in Biotech
Live Poll
Does increased competition between drug manufacturers generally lead to better outcomes for patients?
BioMarin has entered a licensing agreement with GC Biopharma and Hanmi Pharm to acquire global rights for their experimental Fabry disease treatment. The deal includes an upfront payment of $70 million and up to $405 million in future milestone payments.
Why it matters
This acquisition aims to provide a more convenient treatment alternative to current intravenous therapies for patients with Fabry disease. BioMarin intends to use this therapy to compete in the market and potentially expand its patient reach beyond its existing franchise.
The experimental drug, HM15421/GC1134A, is an enzyme replacement therapy currently being tested in a phase 1/2 clinical trial. Unlike existing treatments that require intravenous infusion every two weeks, this candidate is designed for subcutaneous injection once per month.
The players
BioMarin
A biotechnology company that focuses on developing therapies for rare genetic diseases.
GC Biopharma
A South Korean pharmaceutical company specializing in plasma proteins and vaccines.
Hanmi Pharm
A South Korean pharmaceutical company known for its research and development in drug discovery.
The details
The licensing agreement grants BioMarin rights to the drug worldwide, excluding South Korea, where the developers retain commercialization rights. The therapy is currently undergoing clinical assessment in the U.S., Argentina, and South Korea, measuring kidney function and other endpoints over 48 weeks.
Timeline
2025: South Korean companies initiated the phase 1/2 clinical study.
2025: Galafold generated $521.7 million in net product sales.
October 29, 2026: BioMarin officially announced the licensing deal.
Mid-2030s: The company targets peak annual sales for Galafold of $1.4 billion.
The Tech Race
The introduction of a monthly subcutaneous injection seeks to challenge the long-standing standard of care established by existing therapies like Fabrazyme and Elfabrio. This move positions BioMarin to replace labor-intensive intravenous treatment cycles with more accessible therapeutic options.
Patients currently managing Fabry disease could eventually gain access to a treatment that replaces biweekly intravenous infusions with a monthly subcutaneous shot. This development could reduce the frequency of clinical visits and improve convenience for those dependent on long-term enzyme therapy.
The takeaway
This licensing deal highlights the growing industry focus on increasing patient compliance through less invasive drug delivery methods. Implementing monthly rather than biweekly dosing may serve as a crucial differentiator for new therapies entering the crowded rare disease market.
Further reading
Learn more about emerging innovations in the Biotech sector.
Live Poll
Does increased competition between drug manufacturers generally lead to better outcomes for patients?
